Sotera Health Company Common Stock
SHC
$18.80
-0.48%
Sotera Health Company provides sterilization, analytical lab testing, and advisory services to ensure the safety of medical, pharmaceutical, and food products. Operating through its Sterigenics, Nordion, and Nelson Labs segments, the company is a leading outsourced sterilization provider, particularly in gamma irradiation and EO processing. The current investor narrative centers on the company's robust recovery from litigation-related overhangs, with a 71% stock price surge over the past year reflecting improving operational performance and market sentiment. Recent analyst actions, including upgrades from Citigroup and Goldman Sachs, highlight growing confidence in its growth trajectory and margin expansion.…
SHC
Sotera Health Company Common Stock
$18.80
Related headlines
Investment Opinion: Should I buy SHC Today?
Based on the analysis, I rate SHC as a Buy. The company is experiencing strong revenue growth, improving margins, and has a favorable analyst consensus. The forward PE of 17.77x is attractive relative to the industry average of 22x, and the average analyst target of $20.44 implies 8.1% upside. The PEG ratio of 0.95 suggests the stock is reasonably valued relative to its growth rate.
Sign up to view all
SHC 12-Month Price Forecast
The AI assessment is bullish, driven by the company's strong growth trajectory, attractive forward valuation, and positive analyst sentiment. However, the high debt and litigation risks warrant caution. The stance would be upgraded to high confidence if revenue growth accelerates above 6% and debt levels decline. Conversely, a downgrade to neutral would occur if litigation costs escalate or revenue growth decelerates below 3%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Sotera Health Company Common Stock's 12-month outlook, with a consensus price target around $22.72 and implied upside of +20.9% versus the current price.
Average Target
$22.72
0 analysts
Implied Upside
+20.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$18 - $25
Analyst target range
Analyst coverage includes 9 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.7 (where 1 is Strong Buy and 5 is Sell). The average target price is $20.44, implying an 8.1% upside from the current price of $18.91. The distribution is bullish, with no Sell ratings, and recent actions include upgrades from Citigroup (Buy) and Goldman Sachs (Buy), while Piper Sandler moved from Neutral to Overweight in January 2026. The target range spans from $16.00 (low) to $24.00 (high), with the high target suggesting a 26.9% upside, possibly reflecting expectations of continued margin expansion and revenue growth. The low target implies a 15.4% downside, which could be driven by concerns over litigation costs or competitive pressures. The relatively wide spread of $8.00 indicates moderate uncertainty, but the overall sentiment is positive, with analysts expecting the company to benefit from its leading market position in sterilization services.
Bulls vs Bears: SHC Investment Factors
Sotera Health presents a compelling growth story with accelerating revenue, strong margins, and bullish analyst sentiment. However, the high debt load, elevated trailing valuation, and litigation risks temper the enthusiasm. Currently, the bull case has stronger evidence, driven by the forward earnings growth and analyst upgrades, but the key tension is whether the company can deliver the expected EPS growth to justify the valuation. If earnings fall short, the stock could face significant downside given its high beta and leverage.
Bullish
- Strong Revenue Growth Acceleration: Q4 2025 revenue grew 4.56% YoY to $303.44M, with sequential acceleration from $254.52M in Q1 to $303.44M in Q4. This indicates strengthening demand for sterilization services, particularly in medical devices and pharmaceuticals.
- High Forward Earnings Growth Expected: Forward PE of 17.77x vs trailing PE of 65.33x implies the market expects EPS to jump from $0.29 to $1.26, a 334% increase. This reflects a strong growth outlook, with analysts estimating EPS of $1.26 for the next fiscal year.
- Analyst Consensus is Bullish: With 9 analysts, the consensus is 'Buy' (mean score 1.7), and the average target price of $20.44 implies 8.1% upside. Recent upgrades from Citigroup and Goldman Sachs, plus Piper Sandler's move to Overweight, signal growing confidence.
- High Gross and Operating Margins: Gross margin is 55.48% and operating margin is 33.75%, indicating strong pricing power and operational efficiency. This supports the company's ability to generate robust cash flows and invest in growth.
Bearish
- High Debt-to-Equity Ratio: Debt-to-equity is 3.75x, indicating significant leverage. This increases financial risk, especially if interest rates remain high or cash flows decline, potentially constraining growth investments.
- Trailing PE is Extremely High: Trailing PE of 65.33x is 197% above the industry average of 22x. This suggests the stock is expensive on current earnings, and any earnings miss could lead to a sharp de-rating.
- Beta of 1.775 Indicates High Volatility: With a beta of 1.775, the stock is 77.5% more volatile than the market. This means larger swings in both directions, which may not suit risk-averse investors.
- Litigation Overhang Remains: The company has faced litigation related to its Sterigenics segment, and while the stock has recovered, ongoing legal risks could resurface, causing uncertainty and potential financial liabilities.
SHC Technical Analysis
Sotera Health's stock has exhibited a strong uptrend over the past year, with a 1-year price change of +70.98%, significantly outperforming the S&P 500's +21.46%. The current price of $18.91 sits at 95.2% of its 52-week range (low $11.12, high $19.85), indicating the stock is trading near its highs, which suggests strong momentum but also potential overextension. The 6-month change of +6.54% is modest compared to the 1-year gain, implying the rally has been front-loaded, with recent consolidation near the highs.
Beta
1.77
1.77x market volatility
Max Drawdown
-32.1%
Largest decline past year
52-Week Range
$13-$20
Price range past year
Annual Return
+19.4%
Cumulative gain past year
| Period | SHC Return | S&P 500 |
|---|---|---|
| 1m | +5.9% | +4.0% |
| 3m | +23.4% | +5.3% |
| 6m | +7.7% | +12.6% |
| 1y | +19.4% | +20.1% |
| ytd | +6.3% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SHC Fundamental Analysis
Sotera Health's revenue trajectory shows steady growth, with the latest quarter (Q4 2025) reporting revenue of $303.44 million, a 4.56% YoY increase. Over the past four quarters, revenue has grown from $254.52 million in Q1 2025 to $303.44 million in Q4 2025, indicating a sequential acceleration. The company's service segment, which generated $259.04 million in Q4, is the primary growth driver, while product revenue contributed $44.40 million. This growth is supported by strong demand for sterilization services, particularly in the medical device and pharmaceutical sectors.
Quarterly Revenue
$303441000.0B
2025-12
Revenue YoY Growth
+4.6%
YoY Comparison
Gross Margin
54.7%
Latest Quarter
Free Cash Flow
$147129000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SHC Overvalued?
Given that Sotera Health is profitable, the PE ratio is the primary valuation metric. The trailing PE is 65.33x, while the forward PE is 17.77x, indicating the market expects significant earnings growth. The gap between trailing and forward PE suggests a projected EPS increase from $0.29 to $1.26, reflecting a strong growth outlook. Compared to the industry average PE of 22x (from valuation data), Sotera trades at a 197% premium on a trailing basis, but on a forward basis, it is at a 19% discount, implying the market is pricing in substantial future earnings growth.
PE
65.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 19x~160x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant due to a debt-to-equity ratio of 3.75x, which amplifies interest expense (Q4 interest expense was $35.05M) and reduces net income. The company's net margin is only 6.7%, leaving little room for error. Additionally, the trailing PE of 65.33x implies high expectations; any earnings miss could trigger a sharp sell-off. Cash flow generation is positive (FCF TTM $147.13M), but high debt service costs consume a large portion of operating cash flow.
FAQ
The key risks are: 1) High debt-to-equity of 3.75x, which increases financial vulnerability. 2) Litigation overhang from Sterigenics, which could result in significant costs. 3) High beta of 1.775, leading to large price swings. 4) Competitive pressures and regulatory changes in sterilization. The most severe risk is a litigation loss that could impair the balance sheet.
The 12-month forecast is bullish with a base case target of $20.44 (50% probability), bull case of $24.00 (30% probability), and bear case of $16.00 (20% probability). The most likely scenario is the base case, assuming steady growth and no major setbacks. The stock is expected to trade in the range of $16-$24, with an average upside of 8.1%.
On a trailing basis, SHC is overvalued with a PE of 65.33x vs the industry average of 22x. However, on a forward basis, it is undervalued with a PE of 17.77x, which is 19% below the industry average. This implies the market expects significant earnings growth. The PEG ratio of 0.95 suggests the stock is fairly valued relative to its growth rate.
SHC is a good buy for investors seeking growth, given its strong revenue acceleration and forward PE below the industry average. The analyst consensus is Buy with an average target of $20.44, implying 8.1% upside. However, the high debt and beta mean it's not suitable for risk-averse investors. If you believe the company can achieve its EPS growth estimates, the risk/reward is favorable.
SHC is more suitable for long-term investment (3-5 years) due to its growth potential and the essential nature of its services. The high beta makes it volatile for short-term trading, but the forward PE suggests significant earnings growth ahead. A minimum holding period of 2-3 years is recommended to allow the growth story to play out and to ride out volatility.